FDA Commissioner Marty Makary stepped down Tuesday after a turbulent 13-month tenure, pushed out by Health and Human Services Secretary Robert F. Kennedy Jr. amid mounting pressure from pro-life groups, pharmaceutical executives, and Republican lawmakers who said the agency had drifted from the administration's agenda.
Kyle Diamantis, the FDA's deputy commissioner for food, will serve as acting commissioner while a search for a permanent replacement gets underway, Fox News Digital reported, citing a White House official.
The resignation landed one day before Makary was set to testify in front of the Senate Appropriations Committee, a hearing he will now skip. It capped weeks of public friction between the commissioner and key constituencies inside the Trump coalition, friction that ultimately proved fatal to his position.
A White House official told Fox News Digital the resignation had to do with "process at the FDA" rather than any single policy dispute. The same official said there was "no bad blood." But the polite framing obscured a sharper reality: Kennedy pushed for Makary's removal, and the White House approved it.
Newsmax reported that an administration official told Politico directly that Kennedy himself made the decision. The Wall Street Journal had reported Friday, days before the resignation became official, that President Trump had already signed off on a plan to fire Makary, citing three sources familiar with the matter.
When reporters asked Trump on Friday whether Makary would be fired, the president offered a careful non-denial:
"I've been reading about it, but I know nothing about it."
By Tuesday afternoon, as he departed the White House for a trip to China, Trump struck a warmer tone. He called Makary a "great guy" and offered measured praise:
"He's a great doctor and he was having some difficulty, but he's going to go on and he's going to do well."
Trump followed up with a Truth Social post thanking Makary for his service and announcing the acting appointment. "So much was accomplished under his leadership," Trump wrote. "He was a hard worker, who was respected by all, and will go on to have an outstanding career in Medicine."
The gracious public send-off masked the depth of frustration that had been building for months. Pro-life organizations, a constituency that helped deliver Trump's winning coalition, had grown openly hostile toward Makary's handling of abortion-related drug policy at the FDA.
Under Makary's leadership, the FDA left intact rules allowing mifepristone to be prescribed online and shipped through the mail. Last year, the agency approved a new generic version of the pill. For pro-life advocates who expected the Trump FDA to tighten access to chemical abortion drugs, these decisions felt like a betrayal.
Live Action president Lila Rose had told Fox News Digital ahead of the resignation that the situation demanded action:
"President Trump and Health and Human Services Secretary Kennedy must end this now, remove Commissioner Makary, stop the mail order abortion scheme, and pull these child-killing drugs from the market."
Republican Missouri Sen. Josh Hawley was blunt in his reaction to the news, telling Fox News Digital he was "glad" Makary was leaving. Hawley laid out a bill of particulars that went beyond mifepristone:
"He was terrible to the pro-life movement. He attempted to place pro-abortion lawyers in key positions. He not only slow-walked a safety review of the dangerous abortion drug mifepristone; he greenlit a new abortion drug that sends 11% of women to the emergency room."
Hawley called the resignation "an opportunity for the FDA to reset and protect life." That framing, reset, not merely replace, captured the depth of conservative dissatisfaction with the agency's direction under Makary.
The criticism extended beyond Capitol Hill. Earlier in May, a Trump administration official had told Fox News Digital bluntly: "What a mess Makary turned out to be." The same official said Makary had made "every pro-life advocate" feel that "their concerns are an afterthought." The official added: "The arrogance is stunning."
Makary's departure follows a pattern of high-profile exits from the Trump administration this year, including former Homeland Security Secretary Kristi Noem and former Attorney General Pam Bondi.
AP News reported that Makary faced complaints not only from anti-abortion activists but also from health industry executives and vaping lobbyists, a broad coalition of discontent that left him without a reliable base of support inside the administration or among its allied interest groups.
That isolation made him vulnerable. When Kennedy decided to act, there was no constituency willing to fight for Makary's survival.
Susan B. Anthony Pro-Life America President Marjorie Dannenfelser had gone further than criticizing the commissioner. Earlier in May, she told the Wall Street Journal that "Trump is the problem" on abortion issues, a remarkable statement from a leader whose organization has spent heavily to elect Republican candidates. Dannenfelser said candidates who want her group's $160 million in the midterms and 2028 presidential election must commit "to pro-life action at the national level."
That kind of public pressure from a major donor organization does not go unnoticed. Makary's exit may ease some of that tension, but only if his successor moves in a direction the pro-life movement considers acceptable.
The man stepping into the acting role comes with a background that pro-life advocates may find reassuring, and that the White House was quick to highlight.
White House spokesperson Kush Desai told Fox News Digital that Diamantis, an attorney, had once been assigned by his law firm to represent Planned Parenthood in a case. He refused.
"Kyle Diamantas was a junior legal associate who was assigned to that case by his superiors. He expressed his objections to representing Planned Parenthood based on his personal convictions, and ultimately removed himself from the case."
White House officials praised the move, and the administration clearly sees Diamantis' pro-life credentials as a selling point. Kennedy, in a post on X, thanked Diamantis for stepping in and credited him with "remarkable wins on the MAHA food agenda."
The broader pattern of federal personnel changes this year has drawn scrutiny, but in this case the administration appears to be signaling a deliberate course correction rather than mere housekeeping.
Just the News noted that Makary's departure came on May 12, 2026, after 13 months in the role, a short tenure even by the standards of an administration that has seen significant turnover.
Kennedy's public statement on Makary's departure was generous, perhaps more generous than the behind-the-scenes reality warranted. In his X post, the HHS secretary wrote:
"Marty, you took on entrenched interests, challenged the status quo, and never lost sight of the American people we serve. You pushed forward critical reforms and helped advance our mission to Make America Healthy Again."
Kennedy added that "the search for a new Commissioner is already underway, and we will move forward with urgency." That urgency matters. The FDA regulates roughly a quarter of the American consumer economy, food, drugs, medical devices, tobacco. Leaving it in acting-commissioner limbo for an extended period carries real costs.
The administration has not publicly named any candidates for the permanent role. The process will likely require Senate confirmation, which means the nominee will face questions about every controversy that dogged Makary, and then some.
This episode also fits into a broader story of internal clashes and forced departures across the executive branch. The question is whether the administration treats these as growing pains or whether the churn itself becomes a drag on the policy agenda.
The White House's explanation, that this was about "process at the FDA", remains vague. What specific process failures triggered Kennedy's decision? The administration has not said. Makary himself has not spoken publicly since the resignation was announced.
Whether the FDA under new leadership will move to restrict mifepristone access, revisit the generic approval, or take other steps demanded by pro-life groups remains to be seen. Hawley and Rose have made their expectations clear. Dannenfelser has put a dollar figure on hers.
Meanwhile, the steady stream of departures from the administration raises a practical question: at what point does turnover stop being a sign of accountability and start becoming a management problem?
Makary's exit tells a familiar Washington story. A qualified appointee who couldn't, or wouldn't, deliver what the coalition that elected his boss actually wanted. In politics, expertise without alignment is a short lease. And 13 months is about what it buys you.